OBJECTIVE To determine the prostate‐specific antigen (PSA) response and time to PSA or
radiographic progression in men with prostate cancer refractory to bicalutamide and/or …

OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and adverse effects of
nilutamide and to compare this agent with the currently marketed nonsteroidal …

Objectives. To study the ability of nilutamide to induce prostate-specific antigen (PSA)
responses in patients with hormone-resistant prostate cancer who had been exposed to …

Objectives: We performed an exploratory analysis to determine whether there was a
difference between two antiandrogen‐plus‐luteinizing hormone‐releasing hormone …

PURPOSE To determine the therapeutic effects of bicalutamide 200 mg in patients with
prostate cancers of different hormone sensitivities. METHODS Patients with progressive …

Objectives. Bicalutamide is a nonsteroidal competitive inhibitor of androgens at the
androgen receptor. The level of blockade that can be achieved is dependent on the relative …

OBJECTIVE To evaluate the activity of nilutamide as secondary hormonal therapy in patients
with androgen‐independent prostate cancer (AIPC), as treatment options are limited for …

This article presents and discusses data on the tolerability of the antiandrogens, both
steroidal (cyproterone acetate; CPA) and non-steroidal (bicalutamide, flutamide, nilutamide) …

Purpose: We investigate the prostate specific antigen (PSA) response rate with nilutamide
as a second line hormonal agent in patients with advanced prostate cancer in whom …

OBJECTIVES To investigate the efficacy of maximum androgen blockade (MAB) using
flutamide as second‐line hormonal therapy for advanced hormone‐refractory prostate …